The follow up of patients operated for colorectal cancer (CRC) and the early detection of recurrences and metachronous tumors improves significantly the results of treatment and the survival of the patients. Computed Tomography (CT) and fibro-colonoscopy (FCS) are the main applied image diagnostic methods for this aim. Alternative unified method is the CT colonoscopy (CTC -"virtual colonoscopy" ) with i.v. appliance of contrast. A particular group of patients liable to control are those after Miles and Hartmann operation with created colostoma. The performance of CTC and its informativeness in these cases is specific and represents a challenge. For a two-year period were implemented generally 48 "virtual colonoscopies" (CTC) in stoma patients--21 male and 27 female, average age 53.2 ± 9 years. The postoperative interval to the CTC varied 8 to 29 months. The studies were performed on a 32 detector CT - GE: 32 x 0.625mm and rotation time 0.6 sec. with automatic modulation of the dose. The CT images are processed with special software for CTC and analyzed according to standardized system for reporting of findings in CTC - C-RADS. The specific technique for CTC in stoma patients is described. CTC was entirely accomplished in all 48 cases (100%). The duration of the studies varied 10 to 25 min. (average 17 min.). No essential side effects or according to the procedure complications were marked. To one patient a conventional FCS was recommended for accurate assessment of a collapsed bowel segment. Adequate marking of the fecal odds with barium sulfate was marked in all cases. The CTC findings were assessed as normal in 23 cases (48%). In 25 patients (52%) were described pathologic findings of colonic and extra-colonic origin. Conclusions that CTC in patients operated according to the methods of Miles and Hartmann is technically feasible and could be executed for complex assessment of large bowel and extra-colonic abdominal structures. CTC possess the advantage of the possibility for synchronous assessment of the organs and structures in the abdominal cavity, which is economically profitable, saves time and psychical suspense for the patients and avoids the risk of complications and unpleasant experiences of the patient durinf a conventional FCS.
Download full-text PDF |
Source |
---|
Small
January 2025
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Capturing circulating tumor cells (CTCs) in vivo from the bloodstream lessens tumor metastasis and recurrence risks. However, the absence of CTC receptors due to epithelial-mesenchymal transition (EMT), the limited binding capacity of a single ligand, and the complexity of the blood flow environment significantly reduce the efficiency of CTC capture in vivo. Herein, a multivalent ligand-decorated microsphere enrichment system (MLMES) is crafted that incorporates a capture column replete with an immunosorbent that precisely recognizes and binds the stably expressed cluster of differentiation 44 (CD44) and glucose transporter protein 1 (GLUT1) receptors present on the exterior of CTCs.
View Article and Find Full Text PDFLab Chip
January 2025
Institute for Biomedical Materials and Devices (IBMD)/Faculty of Science, University of Technology Sydney, Sydney, NSW, 2007 Australia.
Liquid biopsy provides a minimally invasive approach to characterise the molecular and phenotypic characteristics of a patient's individual tumour by detecting evidence of cancerous change in readily available body fluids, usually the blood. When applied at multiple points during the disease journey, it can be used to monitor a patient's response to treatment and to personalise clinical management based on changes in disease burden and molecular findings. Traditional liquid biopsy approaches such as quantitative PCR, have tended to look at only a few biomarkers, and are aimed at early detection of disease or disease relapse using predefined markers.
View Article and Find Full Text PDFLab Chip
January 2025
Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.
Heterogeneities among tumor cells significantly contribute towards cancer progression and therapeutic inefficiency. Hence, understanding the nature of cancer through liquid biopsies and isolation of circulating tumor cells (CTCs) has gained considerable interest over the years. Microfluidics has emerged as one of the most popular platforms for performing liquid biopsy applications.
View Article and Find Full Text PDFHepatology
January 2025
Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center (CTC), Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Background Aims: Cirrhosis prevalence is increasing, yet costs associated with its chronic, complex care are poorly understood. The aim was to characterize the costs of care for patients with cirrhosis and compare them to other chronic diseases such as heart failure (HF) and chronic obstructive pulmonary disease (COPD), for which the public health burden is better recognized.
Approach: Patients enrolled in Medicare Advantage plans from a large national insurer between 2011-2020 with cirrhosis, HF, and COPD were identified by ICD-9/-10 codes.
J Exp Clin Cancer Res
January 2025
Department of General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
Background: Circulating tumour cells (CTCs) and tumour-derived extracellular vesicles (tdEVs) have great potential for monitoring therapy response and early detection of tumour relapse, facilitating personalized adjuvant therapeutic strategies. However, their low abundance in peripheral blood limits their informative value. In this study, we explored the presence of CTCs and tdEVs collected intraoperatively from a tumour-draining vein (DV) and via a central venous catheter (CVC) prior to tumour resection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!